Jotin Marango - 25 Jul 2025 Form 4 Insider Report for ImageneBio, Inc. (IKNA)

Role
Chief Financial Officer
Signature
/s/ Jotin Marango
Issuer symbol
IKNA
Transactions as of
25 Jul 2025
Net transactions value
-$79,451
Form type
4
Filing time
29 Jul 2025, 21:32:38 UTC
Previous filing
02 Feb 2024
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Marango Jotin Chief Financial Officer IMAGENEBIO, INC., 645 SUMMER STREET, SUITE 101, BOSTON /s/ Jotin Marango 29 Jul 2025 0001777513

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IMA Common Stock Award +15,776 15,776 28 Jul 2025 Direct F1
transaction IMA Common Stock Tax liability $79,451 -4,630 -29% $17.16 11,146 28 Jul 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMA Stock Option (Right to Buy) Disposed to Issuer $0 -181,000 -100% $0.000000 0 25 Jul 2025 Common Stock 181,000 Direct F1
transaction IMA Stock Option (Right to Buy) Disposed to Issuer $0 -105,000 -100% $0.000000 0 25 Jul 2025 Common Stock 105,000 Direct F1
transaction IMA Stock Option (Right to Buy) Disposed to Issuer $0 -397,199 -100% $0.000000 0 25 Jul 2025 Common Stock 397,199 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Jotin Marango is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 In connection of the closing of the Merger between the Company (formerly known as Ikena Oncology, Inc. ("Ikena")) and Inmagene Biopharmaceuticals, shares of the combined company were issued on July 28 in exchange for certain options held by the holder in Ikena.